Lucid Diagnostics (LUCD) Competitors $0.78 +0.01 (+1.31%) (As of 12/20/2024 05:40 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends LUCD vs. SGHT, LAKE, PDEX, BWAY, NVRO, SRTS, ZJYL, TLSI, TELA, and GUTSShould you be buying Lucid Diagnostics stock or one of its competitors? The main competitors of Lucid Diagnostics include Sight Sciences (SGHT), Lakeland Industries (LAKE), Pro-Dex (PDEX), BrainsWay (BWAY), Nevro (NVRO), Sensus Healthcare (SRTS), Jin Medical International (ZJYL), TriSalus Life Sciences (TLSI), TELA Bio (TELA), and Fractyl Health (GUTS). These companies are all part of the "medical equipment" industry. Lucid Diagnostics vs. Sight Sciences Lakeland Industries Pro-Dex BrainsWay Nevro Sensus Healthcare Jin Medical International TriSalus Life Sciences TELA Bio Fractyl Health Sight Sciences (NASDAQ:SGHT) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, community ranking, valuation, dividends and risk. Do analysts recommend SGHT or LUCD? Sight Sciences presently has a consensus price target of $5.12, suggesting a potential upside of 43.42%. Lucid Diagnostics has a consensus price target of $3.63, suggesting a potential upside of 364.15%. Given Lucid Diagnostics' stronger consensus rating and higher probable upside, analysts plainly believe Lucid Diagnostics is more favorable than Sight Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sight Sciences 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.17Lucid Diagnostics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Does the MarketBeat Community believe in SGHT or LUCD? Lucid Diagnostics received 19 more outperform votes than Sight Sciences when rated by MarketBeat users. Likewise, 67.92% of users gave Lucid Diagnostics an outperform vote while only 29.82% of users gave Sight Sciences an outperform vote. CompanyUnderperformOutperformSight SciencesOutperform Votes1729.82% Underperform Votes4070.18% Lucid DiagnosticsOutperform Votes3667.92% Underperform Votes1732.08% Which has higher earnings and valuation, SGHT or LUCD? Lucid Diagnostics has lower revenue, but higher earnings than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSight Sciences$79.54M2.28-$55.55M-$1.02-3.50Lucid Diagnostics$4.19M11.06-$52.67M-$1.14-0.69 Does the media favor SGHT or LUCD? In the previous week, Sight Sciences had 1 more articles in the media than Lucid Diagnostics. MarketBeat recorded 2 mentions for Sight Sciences and 1 mentions for Lucid Diagnostics. Sight Sciences' average media sentiment score of 0.00 equaled Lucid Diagnostics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sight Sciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lucid Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders believe in SGHT or LUCD? 55.5% of Sight Sciences shares are held by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are held by institutional investors. 28.9% of Sight Sciences shares are held by insiders. Comparatively, 8.8% of Lucid Diagnostics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more volatility and risk, SGHT or LUCD? Sight Sciences has a beta of 2.58, suggesting that its stock price is 158% more volatile than the S&P 500. Comparatively, Lucid Diagnostics has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500. Is SGHT or LUCD more profitable? Sight Sciences has a net margin of -63.30% compared to Lucid Diagnostics' net margin of -1,069.87%. Lucid Diagnostics' return on equity of 0.00% beat Sight Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Sight Sciences-63.30% -47.28% -32.72% Lucid Diagnostics -1,069.87%N/A -123.54% SummaryLucid Diagnostics beats Sight Sciences on 11 of the 18 factors compared between the two stocks. Ad WealthPress70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today!Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.>> You can grab your FREE, laminated copies right here << Get Lucid Diagnostics News Delivered to You Automatically Sign up to receive the latest news and ratings for LUCD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LUCD vs. The Competition Export to ExcelMetricLucid DiagnosticsSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$46.35M$4.36B$5.10B$9.08BDividend YieldN/A41.46%4.88%4.21%P/E Ratio-0.6925.0190.8317.14Price / Sales11.0645.671,112.01116.85Price / CashN/A43.4642.0237.88Price / Book-1.667.364.774.78Net Income-$52.67M$13.64M$119.70M$225.60M7 Day Performance-0.56%-2.82%-1.86%-1.23%1 Month Performance-21.82%0.54%11.45%3.07%1 Year Performance-42.99%41.80%30.43%16.48% Lucid Diagnostics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LUCDLucid Diagnostics2.1501 of 5 stars$0.78+1.3%$3.63+364.1%-43.0%$46.35M$4.19M-0.6970News CoverageSGHTSight Sciences3.391 of 5 stars$3.65+2.0%$5.12+40.3%+7.2%$185.27M$81.06M-3.51210News CoverageGap UpLAKELakeland Industries4.5762 of 5 stars$23.88+5.2%$26.50+11.0%+28.5%$176.86M$151.82M-252.221,750Analyst ForecastAnalyst RevisionPDEXPro-Dex2.0625 of 5 stars$48.48-1.9%$52.00+7.3%+181.2%$158.00M$56.80M31.48140BWAYBrainsWay4.1415 of 5 stars$9.46+0.4%$13.17+39.2%+40.9%$157.77M$38.63M95.20120NVRONevro2.1418 of 5 stars$4.15+2.0%$8.05+94.0%-82.0%$155.50M$425.17M-2.231,215Analyst ForecastSRTSSensus Healthcare3.9859 of 5 stars$7.97-2.3%$12.50+56.8%+186.3%$130.63M$24.41M14.3240Positive NewsZJYLJin Medical InternationalN/A$0.80+2.6%N/A-99.0%$123.40M$19.82M0.00245Gap DownTLSITriSalus Life Sciences4.0096 of 5 stars$3.88-0.8%$12.08+211.4%-50.5%$118.31M$26.89M-1.57106Analyst ForecastInsider TradeNews CoverageGap UpTELATELA Bio2.9974 of 5 stars$2.79+0.7%$9.25+231.5%-49.8%$109.90M$58.45M-1.64120GUTSFractyl Health0.8814 of 5 stars$2.11+3.4%$22.00+942.7%N/A$101.49M$120,000.00-0.17102 Related Companies and Tools Related Companies SGHT Alternatives LAKE Alternatives PDEX Alternatives BWAY Alternatives NVRO Alternatives SRTS Alternatives ZJYL Alternatives TLSI Alternatives TELA Alternatives GUTS Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LUCD) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lucid Diagnostics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lucid Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
